Search

Osteosarcoma is the most common primary bone malignancy and has a high tendency of local invasion. Although a lot of studies have focused on chemotherapy and combination chemotherapy regimens in recent years, still, there is no particularly perfect regimen for the treatment of relapsed or metastatic OS, and the prognosis is still relatively poor. As a new therapeutic method, targeted therapy provides a new scheme for patients with osteosarcoma and has a wide application prospect. This article reviews the latest progress of targeted therapy for osteosarcoma, and summarizes the research on the corresponding targets of osteosarcoma through six major pathways. These studies can pave the way for new treatments for osteosarcoma patients who need them.

Wide-bandgap (WBG) Methylammonium (MA)-free based perovskite solar cells (PSCs) have attracted widespread research interests due to their broad applicability in multijunction tandem. Nevertheless, the efficiency of WBG PSCs is restricted by unfulfilled potential in fill factor and large deficits in open-circuit voltage. The imbalanced carrier mobility not only plays a critical role in bulk non-radiative recombination loss but also hinders efficient charge collection for mixed I/Br WBG perovskites. Herein, we introduced additive named 2,8-Diiododibenzothiophene to overcome above issues. Inverted devices with enhanced photostability and a record fill factor of 85.7 % are demonstrated. Moreover, combining the semitransparent WBG PSCs with 1.25 eV-bandgap perovskite bottom cells, we realized 4-terminal tandem devices and a champion PCE of 28 % is achieved. The multifunctional additive strategy demonstrated here, will open new avenues for improving WBG PSCs’ performance.

Published ahead of print May 19, 2017.